Deal Watch: AbbVie Pays Highest Price Yet Seen For Priority Review Voucher
Executive Summary
Depomed deems increased buyout offer from Horizon as insufficient, possibly leaving Horizon to consider alternative acquisitions. Valeant will pay $1bn to acquire Sprout and its just approved female sexual desire disorder drug Addyi.
You may also be interested in...
Sanofi Diabetes Franchise Could Get Boost From Retrophin’s Voucher
Priority review ticket might be used on Type 2 diabetes combo LixiLan, expected to be filed later this year.
CHMP Positive On Safinamide, First New Parkinson’s Therapy In 10 Years
Newron expects partner Zambon to start marketing safinamide in the first half of 2015 in Europe, and to resubmit it soon for U.S. approval. Other positive CHMP opinions this month include Orexigen’s obesity therapy Mysimba and Durata’s antibiotic Xydalba.
Sanofi/Regeneron’s PCSK9 Inhibitor Gets Reassuring CV Data – And A Priority Review Voucher
Alirocumab was associated with lower rate of major cardiovascular events compared to placebo in post-hoc, interim Phase III analysis – boosting chances for FDA approval in 2015. The firm is taking no chances on review period, purchasing a priority review voucher from BioMarin.